---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-067990"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:34:48.689331+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics H1 2023 net loss $5.4M; cash down to $5.1M; FDA meeting on IL-6 test

## Summary
- Net loss $5.4M ($5.24/sh) vs $4.0M ($2.00/sh) in H1 2022; no revenue reported.
- Cash and equivalents fell to $5.1M from $10.1M at Dec 31, 2022; company expects to raise capital near-term.
- R&D expense doubled to $3.0M, driven by clinical trial costs for Symphony IL-6 sepsis test.
- FDA pre-submission meeting on Aug 11, 2023 confirmed 510(k) pathway; company targets submission in H1 2024.
- Sales and marketing expense $302K vs $135K in prior period as company builds commercial infrastructure.

## SEC filing metadata
- accession: 0001213900-23-067990
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/0001213900-23-067990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/ea183606-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-067990
- JSON: https://secwatch.observer/filing/0001213900-23-067990.json
- Plain text: https://secwatch.observer/filing/0001213900-23-067990.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported the six months ended June 30, 2023 results: net income $5.4 million, EPS $5.24 per share.
  - Period: the six months ended June 30, 2023
  - Net income: $5.4 million
  - EPS: $5.24 per share
  - Result: reported results
  source text: The net loss for the six months ended June 30, 2023 was $5.4 million, or $5.24 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390023067990/0001213900-23-067990-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.